The FDA approved dupilumab (Dupixent) for treating allergic fungal rhinosinusitis, a first for the condition, the agency announced on Wednesday. Approval stipulates use in individuals 6 years and ...
FDA approves Regeneron and Sanofi's Dupixent for allergic fungal sinusitis in patients 6 years and older with prior surgery history.
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results